Virax Biolabs GroupVRAX -0.64%37 Days Payable is 8,942.50 as of Sep. 2025, which is 1416% above its 10-year median of 590.04. GuruFocus rates VRAX with a GF Score™ of 37/100 and a GF Value™ of $1.15 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 700 Biotechnology companies, Virax Biolabs Group ranks better than 80.14% on this metric.
The historical rank and industry rank for Virax Biolabs Group's Days Payable or its related term are showing as below:
VRAX'
s Days Payable Range Over the Past 10 Years
Min: 315.51 Med: 590.04 Max: 18359.5
Current: 538.81
During the past 6 years, Virax Biolabs Group's highest Days Payable was 18359.50. The lowest was 315.51. And the median was 590.04.
VRAX's Days Payable is ranked better than 80.14% of 700
companies
in the Biotechnology industry
Industry Median: 113.1
vs VRAX: 538.81
Virax Biolabs Group's Days Payable
increased
from Sep. 2024 (1,368.75) to Sep. 2025 (8,942.50).
It may suggest that Virax Biolabs Groupdelayed paying its suppliers.
Virax Biolabs Group Days Payable Related Terms
Virax Biolabs Group Days Payable Historical Data
* Premium members only.
The historical data trend for Virax Biolabs Group's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Virax Biolabs Group's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Virax Biolabs Group Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Virax Biolabs Group's Days Payable distribution charts can be found below:
* The bar in red indicates where Virax Biolabs Group's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Virax Biolabs Group's Days Payable for the fiscal year that ended in Mar. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Virax Biolabs Group (VRAX) has a Days Payable of 8,942.50 as of Sep. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Virax Biolabs Group and its competitors. This is 1416% above median its historical median of 590.04. Over the past decade, Virax Biolabs Group's Days Payable has ranged from 315.51 to 18,359.50. According to the industry distribution chart, Virax Biolabs Group ranks #139 out of 700 companies in the Biotechnology industry, placing it in the top 19.9%.
Is Virax Biolabs Group's Days Payable too high?
Virax Biolabs Group's current Days Payable of 8,942.50 is 1416% above median its 10-year median of 590.04. Over the past 10 years, this metric has ranged from a low of 315.51 to a high of 18,359.50. The Biotechnology industry median Days Payable is 113.10. Virax Biolabs Group's value of 8,942.50 is 7806.7% above this industry median. Based on the distribution chart, Virax Biolabs Group ranks #139 out of 700 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Virax Biolabs Group has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Virax Biolabs Group's Days Payable compare to BBLG and PKTX?
According to the Biotechnology industry distribution chart, Virax Biolabs Group ranks #139 out of 700 companies for Days Payable. This places Virax Biolabs Group in the top 20% of its industry — outperforming the majority of peers. The industry median Days Payable is 113.10. Virax Biolabs Group's value of 8,942.50 is 7806.7% above this benchmark. Historically, Virax Biolabs Group's own Days Payable has ranged from 315.51 to 18,359.50 over the past decade. While the company's 10-year median is 590.04 vs. the industry median of 113.10, Virax Biolabs Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 700 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Virax Biolabs Group's current Days Payable of 8,942.50 is 7806.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Virax Biolabs Group and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Virax Biolabs Group's current Days Payable is 8,942.50, which is 1416% above median its own 10-year median of 590.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Virax Biolabs Group stock overvalued right now?
Based on GuruFocus' analysis, Virax Biolabs Group (VRAX) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.15, compared to a current price of $3.09 — trading 168.7% above its estimated fair value. The current Days Payable is 8,942.50, which is 1416% above median its 10-year median of 590.04 and 7806.7% above the Biotechnology industry median of 113.10. Virax Biolabs Group's overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Virax Biolabs Group (VRAX), the current Days Payable is 8,942.50 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Virax Biolabs Group (VRAX) Overvalued in 2026?
Based on GuruFocus' analysis, Virax Biolabs Group stock appears to be overvalued.
The current stock price of $3.09 is trading 168.7% above its estimated GF Value™ of $1.15.
GuruFocus considers Virax Biolabs Group to be Significantly Overvalued.
Key valuation signals for VRAX:
Days Payable: 8,942.50 (1416% above median its 10-year median of 590.04)
GF Value™: $1.15 vs. price of $3.09 (168.7% above fair value)
Industry Position: 7806.7% above the Biotechnology median (#139 of 700)
No single metric tells the full story. See the VRAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.
37GF Score
Get the complete analysis for VRAX
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VRAX has been successfully added to your 
